To print: Select File and then Print from your browser's menu

Title: Darbepoetin Alfa Effective for Cancer-Related Anemia When Given Once Every 3 Weeks

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=12957457

Eur J Cancer 2003 Sep;39:14:2026-2034. "Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study"
09/17/2003 10:44:00 AM
By Emma Hitt, PhD

Darbepoetin alfa, given once every 3 weeks, effectively and safely ameliorates anaemia due to chemotherapy, according to the findings of a randomised trial. Anaemia is a common side effect and contributes to fatigue in cancer patients receiving chemotherapy. Recombinant human erythropoietin is often given on a once-a-week dosing schedule. Darbepoetin alfa is a modified long-acting form of endogenous erythropoietin. Dusan Kotasek, MD, with the Ashford Cancer Centre, Australia, and colleagues assessed the feasibility of further reducing the dosing schedule to once every 3 weeks in patients receiving darbepoetin alfa. In the first part of the study, 249 patients (haemoglobin 110 g/L or less) were randomised to receive 1 of 6 doses of darbepoetin alfa (4.5, 6.75, 9.0, 12.0, 13.5 and 15.0 micrograms/kilogram) (n=198) or placebo (n=51) once every 3 weeks for 12 weeks. In second part of the study, patients received open-label darbepoetin alfa for an additional 12 weeks and were evaluated for safety, haemoglobin endpoints and red blood cell transfusions over 6 more weeks of follow-up. The researchers found that darbepoetin alfa given at doses ranging from 4.5 to 15.0 micrograms/kilogram once every 3 weeks was well tolerated and comparable to placebo in terms of safety. In addition, neutralising antibodies were not detected. Furthermore, all doses (from 4.5 to 15 micrograms/kilogram) reduced transfusions compared with placebo and resulted in more than half of patients achieving a haematopoietic response. "While the haemoglobin response rate in the 4.5 microgram/kilogram group (the lowest of the doses studied) was 24%, a substantial proportion of patients had a haematopoietic response at this dose (51%) indicating that clinically meaningful erythropoiesis was evident," the researchers note. They also found that the mean change in haemoglobin tended to increase with increasing darbepoetin alfa dose (p=0.01). "The ability to administer darbepoetin alfa as infrequently as once every 3 weeks...represents an opportunity to simplify the treatment of anaemia in cancer patients undergoing chemotherapy," the researchers conclude.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=12957457

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.